- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
Academic Institute
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 713.441.3771
To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verifying ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combination ... Read more >
Status: Enrolling
Investigator: Gustavo Roman
Study Coordinator: Daniel Arnaud Dominguez
Phone: 346.356.3635
This is a Phase IIa, randomized, double-blinded, placebo-controlled trial to determine the tolerability of L-serine for Mild Cognitive Impairment patients and assess preliminary indications of efficacy. Efficacy will be assessed by cognitive testing,... Read more >
Status: Enrolling
Investigator: William Ondo
Study Coordinator: Daniel Arnaud Dominguez
Phone: 346.356.3635
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.... Read more >
Status: Enrolling
Investigator: Stanley Appel
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neurolog... Read more >
Status: Enrolling
Investigator: Juan Toledo Atucha
Study Coordinator: Reena Boradia
Phone: 713.441.1150
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered ope... Read more >
Status: Open Not Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants wil... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator:
Phone:
This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. Under this study, up to 10 patients with ALS will undergo leukapheresis. Their Tregs will subsequently be isolated and expanded fr... Read more >
Status: Open Not Enrolling
Investigator: Sherif Nagueh
Study Coordinator: Nirali Patel
Phone: 713.441.2116
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Mult... Read more >
Status: Enrolling
Investigator: Juan Toledo Atucha
Study Coordinator: David De Leon Garza
Phone: 346.238.1555
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whethe... Read more >
Status: Enrolling
Investigator: Maria Pascual
Study Coordinator: Victoria Arbones
Phone: 713.441.7650
The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts lo... Read more >
Status: Enrolling
Investigator: Andrew Billnitzer
Study Coordinator: Nijah Russell
Phone: 346.238.2287
Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as M... Read more >
Status: Open Not Enrolling
Investigator: Stanley Appel
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
The purpose of this protocol is to develop and maintain a clinical findings data bank including diagnostic evaluations obtained from medical records sent from prior medical evaluations, diagnostic intake evaluations and follow-up care in the Methodis... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
The purpose of this study is to: Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients Characterize the safety and effectiveness of patisiran and vutrisiran as part ... Read more >
Status: Enrolling
Investigator: Tetsuo Ashizawa
Study Coordinator: Valerie Flores
Phone: 713.363.9803
While solid evidence for direct CNS infection by SARS-CoV-2 is lacking, a consensus has been forming that affected patients are at higher risk of developing neuropsychiatric and neurologic sequelae after overcoming the primary infection, as a consequ... Read more >
Status: Enrolling
Investigator: David Chiu
Study Coordinator:
Phone:
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptoma... Read more >
Status: Open Not Enrolling
Investigator: Stanley Appel
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
The purpose of the this study to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress wi... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks. Participants will be randomized to receive an intravenous infusion of either del-desiran or placebo at the ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Chimaoge Okafor
Phone: 713.363.7729
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Chimaoge Onyechi
Phone: 713.363.7729
Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanism... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator:
Phone:
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Andrea Franco Pando
Phone: 713.441.1150
The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abilities. V... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Jeffrey Ling
Phone: 713.363.7753
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, bioma... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that leve... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work evaluatio... Read more >
Status: Open Not Enrolling
Investigator: Kumar Pichumani
Study Coordinator: Kumar Pichumani
Phone: 713.441.7190
Title: Investigation of central nervous system tumor metabolism in patients undergoing surgical resection PI- Kumar Pichumani, PhD coPI- David Baskin, MD Interest in the clinical potential of tumor intermediary metabolism dates to the 1920, w... Read more >
Status: Open Not Enrolling
Investigator: David Baskin
Study Coordinator: Helga Jones
Phone: 713.363.9388
" Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior ... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator: Melissa Daly
Phone: 713.441.3834
NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma multifor... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator: Melissa Daly
Phone: 713.441.3834
NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma multi... Read more >
Status: Open Not Enrolling
Investigator: Jun Li
Study Coordinator: Stephanie Yan Xuan
Phone: 313.217.1098
This study aims to look at the genetic differences between individuals with neurological disorders and healthy controls, and whether these genetic differences contribute to nerve conduction speeds. We expect that this study will identify a small clus... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: Delrose Vernon
Phone: 346.238.9068
Myasthenia gravis (MG) is a rare autoimmune disorder characterized by autoantibody responses that cause defective transmission of signals at the neuromuscular junction, resulting in a distinctive pattern of weakness. Patients with generalized MG (gMG... Read more >
Status: Enrolling
Investigator: Bing Liao
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), an... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 713.441.3771
The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is impor... Read more >